<DOC>
	<DOCNO>NCT00793429</DOCNO>
	<brief_summary>In study healthy volunteer receive increase dos prucalopride study tolerability cardiac safety prucalopride . The study hypothesis prucalopride dose 10 mg clinically relevant effect cardiovascular safety healthy volunteer .</brief_summary>
	<brief_title>Safety Study Prucalopride Healthy Volunteers</brief_title>
	<detailed_description>Single-centre , double-blind , placebo-controlled , cross-over study 33 healthy volunteer 2 session . Each session consist run-in day baseline assessment , 8 treatment day 5 additional day followup assessment . Subjects randomise start either prucalopride placebo session . The prucalopride dose consecutively escalate 2 mg step per day , start 2 mg 10 mg daily If subject tolerate 10- 8-mg dose , 1 step back dosage scheme allow , 10 8 mg Day 6 , 8 6 mg Day 5 . Subjects intolerance dos le 6 mg , withdrawn study . Repeated dosing ( 6 , 8 10 mg ) continue daily Day 8 , achieve steady-state . During placebo , number placebo tablet consecutively escalate identical way describe prucalopride . Between 2 session , washout period 14 21 day , avoid carry-over effect .</detailed_description>
	<criteria>Aged 18 45 year . Normal weight . Healthy basis prestudy physical examination , medical history , anamnesis , ECG , 24hour Holter monitoring , echocardiogram result blood biochemistry haematology test urinalysis carry 3 week precede randomisation . History suspicion alcohol , barbiturate , amphetamine narcotic abuse . Smoking 10 cigarette , 2 cigar , 2 pipe per day least 6 month prior selection . History cardiac arrhythmia , bronchospastic cardiovascular disease ( e.g . ischaemic heart disease cerebrovascular accident ) , diabetes mellitus , thyrotoxicosis , Parkinsonism . Presence prolong QTc ( Bazett ) ECG screening ( QTc &gt; 450 m male subject , QTc &gt; 470 ms female subject ) . Use concomitant medication , except oral contraceptive paracetamol . Participation investigational drug study 30 day prior first visit . Donation blood 60 day precede first visit . Pregnancy breastfeed female . Female subject childbearing potential without adequate contraceptive protection study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>electrocardiographic safety</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>